Pradaxa 50 deaths

A report about Pradaxa 50 deaths of fatal bleeding worldwide became known November 2011.

About 11 months prior, Pradaxa blood thinner was approved by the FDA and went into the pharmaceutical marketplace.

On December 7, 2011, the FDA announced that patients taking the anticoagulant Pradaxa should continue taking the drug despite post-marketing reports of severe bleeding. People diagnosed with atrial fibrillation are prescribed Pradaxa to reduce the risk of stroke which is associated with AF.

From approval in October 2010 through August 2011, a total of approximately 1.1 million Pradaxa prescriptions were dispensed and approximately 371,000 patients received Pradaxa prescriptions from U.S. outpatient retail pharmacies.

How accurate is the adverse events of Pradaxa 50 deaths? Could there be more deaths that have not been reported?

Currently, the FDA is evaluating post-marketing reports of serious bleeding in patients taking Pradaxa submitted to the Adverse Events Reporting System (AERS) database. While serious, even fatal events have been reported, the FDA is analyzing the events to determine whether the reports of bleeding in patients taking Pradaxa are occurring more commonly than would be expected, based on observations in the large clinical trial that supported the approval of Pradaxa.

Even one Pradaxa death is too many. Pradaxa 50 deaths? If your loved one has died because of Pradaxa fatal bleeding or suffers from severe bleeding because of taking Pradaxa, you may be entitled to a Pradaxa bleeding lawsuit. Please contact Anapol Schwartz to find out what your legal options are.